GSK plans $800m US manufacturing investment
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
Newsletters and Deep Dive digital magazine
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), with Novo Nordisk, Otsuka, AstraZeneca, and Daiichi Sankyo also fo
Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made
Pharma and medtech companies have undergone unprecedented growth through aggressive M&A over the
Editor's Picks
Newsletters and Deep Dive
digital magazine